Atezolizumab + Bevacizumab

Treatment for Liver cancer due to NASH

Typical Dosage: Atezolizumab 1200mg IV every 3 weeks + Bevacizumab 15mg/kg IV every 3 weeks

Effectiveness
88%
Safety Score
35%
Clinical Trials
10
Participants
3K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Atezolizumab 1200mg IV every 3 weeks + Bevacizumab 15mg/kg IV every 3 weeks
Time to Effect
1-2 months
Treatment Duration
until progression or unacceptable toxicity
Evidence Quality
HIGH
Number Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
5(Treat 5 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$300,000
Monitoring:$8,000
Side Effect Mgmt:$15,000
Total Annual:$323,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POOR
ICER
$400,000/QALY
QALYs Gained
0.4
Outcome-Based Costs
Cost per Responder
$1,196,296
Cost per Remission
$5,383,333
Comparison vs Sorafenib
Cost Difference
+$250,000/year
More expensive
QALY Difference
+0.40 QALYs
Better outcomes
Dominance
No dominance
Atezolizumab + Bevacizumab Outcomes

for Liver cancer due to NASH

Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+27%
Remission Rate
+6%
Common Side Effects
Hypertension (grade 3-4)
+23%
Fatigue
+42%
Diarrhea
+24%
Proteinuria (grade 3-4)
+8%
Hemorrhage/Bleeding (grade 3-4)
+15%
Immune-related hepatitis
+10%

Sources:

nih.gov
nih.gov
researchgate.net

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

FIX IT
Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov